Literature DB >> 10960637

Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.

A D Santin1, S Bellone, A Ravaggi, S Pecorelli, M J Cannon, G P Parham.   

Abstract

OBJECTIVE: To evaluate the potential of dendritic cells pulsed with acid-eluted peptides derived from autologous ovarian cancer cells for eliciting a tumor-specific cytotoxic T cell response in women with advanced ovarian cancer.
METHODS: CD8+ T lymphocytes derived from peripheral blood mononuclear cells stimulated in vitro with autologous ovarian tumor peptide-pulsed dendritic cells were tested for their ability to induce an HLA class I-restricted cytotoxic T lymphocyte response against autologous tumor cells. To correlate cytotoxic activity by cytotoxic T lymphocytes with T cell phenotype, we used two-color flow cytometric analysis of surface markers and intracellular cytokine expression (interferon-gamma versus interleukin-4).
RESULTS: CD8+ cytotoxic T lymphocyte responses against autologous ovarian tumor cells were elicited in three consecutive women who had advanced ovarian cancer. Although cytotoxic T lymphocyte populations from all women expressed strong cytolytic activity against autologous tumor cells, they did not lyse autologous lymphoblasts or Epstein-Barr virus-transformed cell lines, and they showed negligible cytotoxicity against the natural killer-sensitive cell line K-562. Cytotoxicity against the autologous tumor cells was significantly inhibited by anti-HLA class I (W6/32) and anti-HLA-A2 (BB7-2) monoclonal antibodies. CD8+ cytotoxic T lymphocytes expressed variable levels of CD56 and preferentially expressed interferon-gamma rather than interleukin-4.
CONCLUSIONS: Peptide-pulsed dendritic cells induced specific CD8+ cytotoxic T lymphocytes that killed autologous tumor cells from women with advanced ovarian cancer. This finding might contribute to the development of active or adoptive immunotherapy for residual or resistant ovarian cancer after standard surgery and cytotoxic treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960637     DOI: 10.1016/s0029-7844(00)00916-9

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  19 in total

Review 1.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

2.  Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer.

Authors:  Tonya J Webb; Xiangming Li; Robert L Giuntoli; Pablo H H Lopez; Christoph Heuser; Ronald L Schnaar; Moriya Tsuji; Christian Kurts; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Res       Date:  2012-05-30       Impact factor: 12.701

Review 3.  Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Authors:  Dmitriy Zamarin; Amir A Jazaeri
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

4.  Establishment of specific cytotoxic T lymphocyte culture system and its inhibitory effect on ovarian cancer.

Authors:  Mingxing Sui; Lihui Si; Tianmin Xu; Manhua Cui
Journal:  Oncol Lett       Date:  2016-09-28       Impact factor: 2.967

5.  Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments.

Authors:  Gautam N Shenoy; Jenni Loyall; Charles S Berenson; Raymond J Kelleher; Vandana Iyer; Sathy V Balu-Iyer; Kunle Odunsi; Richard B Bankert
Journal:  J Immunol       Date:  2018-11-16       Impact factor: 5.422

6.  T cell density and location can influence the prognosis of ovarian cancer.

Authors:  Ahmad Al-Attar; Mohamed Shehata; Lindy Durrant; Paul Moseley; Suha Deen; Stephen Chan
Journal:  Pathol Oncol Res       Date:  2009-12-19       Impact factor: 3.201

Review 7.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

8.  Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.

Authors:  Tonya J Webb; Robert L Giuntoli; Ophelia Rogers; Jonathan Schneck; Mathias Oelke
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 9.  Cellular immunotherapy for ovarian cancer.

Authors:  Martin J Cannon; Timothy J O'Brien
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

10.  Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.

Authors:  Sarah F Adams; Douglas A Levine; Mark G Cadungog; Rachel Hammond; Andrea Facciabene; Narciso Olvera; Stephen C Rubin; Jeff Boyd; Phyllis A Gimotty; George Coukos
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.